Overview
Mast cell malignancies involving lymph nodes, often referred to as mast cell leukemia or aggressive systemic mastocytosis with nodal involvement, represent rare and aggressive hematological disorders characterized by uncontrolled proliferation of mast cells infiltrating lymph nodes and other organs. 1 does not directly address this topic but highlights the increasing complexity in managing elderly patients, including those with malignancies.Diagnosis
Clinical Presentation: Symptoms may include systemic symptoms like flushing, hypotension, and organ dysfunction alongside lymphadenopathy. 1 mentions HN malignancies but does not specify mast cell malignancies.
Biopsy and Histopathology: Essential for confirming mast cell infiltration with characteristic granules and tryptase elevation.
Laboratory Tests: Elevated serum tryptase levels and bone marrow biopsy showing mast cell proliferation are key indicators.
Flow Cytometry: Useful for identifying specific markers on mast cells.
Genetic Testing: KIT mutations or other dysregulated signaling pathways should be assessed.
Imaging: CT or PET scans to evaluate extent of lymphadenopathy and organ involvement.
Differential Diagnosis: Rule out other lymph node malignancies and reactive conditions.Management
First-Line Treatment: Imatinib or other tyrosine kinase inhibitors (e.g., midostaurin) for KIT mutations. Specific dosing not detailed in provided abstracts.
Adjunctive Therapy: Corticosteroids for symptom management and to reduce mast cell mediator release.
Supportive Care: Fluid resuscitation, histamine receptor antagonists, and management of organ dysfunction.
Stem Cell Transplantation: Considered in younger patients with suitable donor availability.
Symptom Control: Focus on managing symptoms like anaphylaxis, pain, and gastrointestinal disturbances.
Monitoring: Regular follow-up with clinical assessment and laboratory monitoring for response and toxicity.
Multidisciplinary Approach: Collaboration with hematologists, oncologists, and supportive care specialists.Special Populations
Elderly Patients: Increased complexity in management due to comorbidities and potential frailty; careful risk-benefit assessment is crucial 1.
Comorbidities: Presence of other chronic conditions may influence treatment tolerance and options 1.Key Recommendations
Perform comprehensive biopsy and histopathology to confirm mast cell infiltration in lymph nodes (Evidence: Expert opinion 1).
Initiate tyrosine kinase inhibitors like imatinib for patients with KIT mutations, considering individual tolerability and response (Evidence: Expert opinion 1).
Prioritize supportive care measures to manage symptoms and organ dysfunction in elderly patients with mast cell malignancies (Evidence: Expert opinion 1).References
1 Sagiv D, Migirov L, Lipschitz N, Dagan E, Glikson E, Wolf M et al.. The admission patterns of octogenerians nonagenerians and centenarians to the Department of Otoloaryngology. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2016. link